Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov recruiting set. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting interventional studies whose public record uses ctDNA or MRD to guide treatment, or lists it as a primary endpoint. 110 studies from 454 registry hits. Last synced Nov 14, 2026, 9:51 PM EST.
Befotertinib Plus Chemotherapy With an MRD-guided Adaptive Strategy for Treatment Escalation and Response Optimization in EGFR-mutated NSCLC Patients
Guangzhou University of Traditional Chinese Medicine · 2 locations · Updated 2026-11-04
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
Peking University People's Hospital · 1 locations · Updated 2026-10-26
ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase
Shuanghu Yuan · 3 locations · Updated 2026-08-07
A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy
Guangdong Association of Clinical Trials · 4 locations · Updated 2026-05-26
ctDNA-MRD Guided Consolidation Toripalimab in Stage IB-IIIA NSCLC
Sun Yat-sen University · 1 locations · Updated 2026-04-23
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
Second Xiangya Hospital of Central South University · 20 locations · Updated 2026-03-09
Circulating Tumor DNA Guided Treatment Monitoring in Advanced Lung Cancer
Zealand University Hospital · 5 locations · Updated 2026-01-09
Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)
Guangdong Association of Clinical Trials · 2 locations · Updated 2026-01-05
A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC
Shanghai Chest Hospital · 1 locations · Updated 2025-11-26
PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC
Sun Yat-sen University · 1 locations · Updated 2025-05-23
Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Peking University People's Hospital · 1 locations · Updated 2025-04-16
MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC
The First Affiliated Hospital of Zhengzhou University · 1 locations · Updated 2023-03-17
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.